Acid salts of valproic acid having the structure: ##STR1## wherein M is potassium, cesium or rubidium. The salts of the invention are useful in the treatment of epileptic seizures, and can be conveniently formulated into oral dosage forms.
The object of the invention is a tablet sustaining release for more than 8 hours, the active ingredient of which is constituted by the complex formed between one mole of valproic acid and one mole of sodium valproate.
5212326 - Sodium hydrogen divalproate oligomer - Owned by Abbott Laboratories (Abbott Park, IL) [*] Notice:The portion of the term of this patent subsequent to January 29, 2008 has been disclaimed.
This invention concerns certain diethyl- or dipropylacetic acid salts of sodium valproate which have physiological properties similar to those of valproic acid or sodium valproate but show highly superior stability characteristics.
There is described a process for the production of a substantially anhydrous salt of an organic acid which comprises reacting a basic compound of a metal with the appropriate organic acid, removing a substantial proportion of water present so as to produce the salt or its hydrate as a liquid phase and then dissolving the liquid phase in a non-aqueous solvent.
This invention concerns certain diethyl- or dipropylacetic acid salts of sodium valproate which have physiological properties similar to those of valproic acid or sodium valproate but show highly superior stability characteristics.
New pharmaceutical composition based on valproic acid and one of the pharmaceutically acceptable salts thereof, obtained by a new galenic preparation process which makes it possible to improve and simplify the galenic production, this composition also containing excipients which favorably modify its kinetics and its bioavailability.
